Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
Open Access
- 1 June 2012
- journal article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. 5, 111-117
- https://doi.org/10.2147/ott.s23273
Abstract
The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib's efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.Keywords
This publication has 40 references indexed in Scilit:
- Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokineticsEuropean Journal of Clinical Pharmacology, 2011
- Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinomaBMC Cancer, 2011
- Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell CarcinomaEuropean Urology, 2011
- Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesBJU International, 2011
- Influence of mild and moderate hepatic impairment on axitinib pharmacokineticsInvestigational New Drugs, 2010
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell CancerJournal of Clinical Oncology, 2009
- Molecular Targeted Therapies for Solid Tumors: Management of Side EffectsOncology Research and Treatment, 2009
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal CarcinomaJournal of Clinical Oncology, 2008
- Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane GhostsThe American Journal of Pathology, 2004
- Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens.1996